Ascendis Pharma A/S $ASND Shares Sold by Candriam S.C.A.

Candriam S.C.A. reduced its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 8.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 178,956 shares of the biotechnology company’s stock after selling 16,159 shares during the period. Candriam S.C.A. owned approximately 0.29% of Ascendis Pharma A/S worth $35,578,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rhumbline Advisers raised its holdings in Ascendis Pharma A/S by 4.0% in the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 55 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Ascendis Pharma A/S by 1.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company’s stock valued at $1,209,000 after purchasing an additional 58 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Ascendis Pharma A/S by 0.6% during the second quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company’s stock worth $2,103,000 after buying an additional 73 shares in the last quarter. Jones Financial Companies Lllp lifted its position in Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after buying an additional 83 shares in the last quarter. Finally, Main Management ETF Advisors LLC boosted its stake in Ascendis Pharma A/S by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 5,864 shares of the biotechnology company’s stock worth $1,012,000 after buying an additional 96 shares during the last quarter.

Ascendis Pharma A/S Trading Down 0.1%

ASND opened at $222.03 on Tuesday. The stock’s 50-day moving average price is $213.59 and its 200 day moving average price is $203.87. Ascendis Pharma A/S has a 12-month low of $118.03 and a 12-month high of $242.00. The firm has a market cap of $13.76 billion, a price-to-earnings ratio of -50.01 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $250.71 million during the quarter, compared to the consensus estimate of $246.91 million. On average, research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $220.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. Royal Bank Of Canada increased their price target on shares of Ascendis Pharma A/S from $245.00 to $250.00 and gave the company an “outperform” rating in a research note on Tuesday, January 20th. Barclays started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $342.00 price objective for the company. Raymond James Financial started coverage on Ascendis Pharma A/S in a research report on Friday, October 17th. They issued a “strong-buy” rating and a $271.00 target price on the stock. Finally, Wolfe Research started coverage on Ascendis Pharma A/S in a research report on Tuesday, November 18th. They set a “peer perform” rating and a $255.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $270.76.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.